Pfizer’s Tanezumab REMS Faces US FDA Doubts Heading Into Panel Review

Knee replacement X-ray
Osteoarthritis progression leading to total joint replacement is among the safety issues flagged in FDA's review of tanezumab. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers